David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$397M |
| 2 |
YHOO
Yahoo Inc
YHOO
|
+$342M |
| 3 |
Bank of America
BAC
|
+$322M |
| 4 |
Citigroup
C
|
+$260M |
| 5 |
Booking.com
BKNG
|
+$219M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCP
PRECISION CASTPARTS CORP
PCP
|
+$637M |
| 2 |
BRCM
BROADCOM CORP CL-A
BRCM
|
+$397M |
| 3 |
Gilead Sciences
GILD
|
+$358M |
| 4 |
Phillips 66
PSX
|
+$330M |
| 5 |
Apple
AAPL
|
+$320M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 13.78% |
| 2 | Technology | 11.11% |
| 3 | Financials | 10% |
| 4 | Consumer Discretionary | 8.83% |
| 5 | Communication Services | 8.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2951
S&T Bancorp
STBA
$1.77B
| $328K | ﹤0.01% |
+12,744
| New | +$334K |
|
|
BBBY
2952
CALL
DELISTED
Bed Bath & Beyond Inc
BBBY
| $328K | ﹤0.01% |
6,600
-39,000
| -86% | -$1.83M |
|
|
ZEUS
2953
DELISTED
Olympic Steel
ZEUS
| $327K | ﹤0.01% |
+18,878
| New | +$224K |
|
|
SUM
2954
DELISTED
Summit Materials, Inc. Class A Common Stock
SUM
| $326K | ﹤0.01% |
+17,507
| New | +$286K |
|
|
JMEI
2955
PUT
DELISTED
Jumei International Holding Limited American depositary shares, each representing ten Class A ordina
JMEI
| $326K | ﹤0.01% |
5,000
+1,000
| +25% | +$64.5K |
|
|
FBNK
2956
DELISTED
First Connecticut Bancorp, Inc
FBNK
| $325K | ﹤0.01% |
20,346
-3,247
| -14% | -$52.7K |
|
2957
Hancock Whitney
HWC
$5.96B
| $324K | ﹤0.01% |
+14,115
| New | +$332K |
|
2958
CoStar Group
CSGP
$13.2B
| $323K | ﹤0.01% |
+17,160
| New | +$304K |
|
2959
Scholastic
SCHL
$761M
| $323K | ﹤0.01% |
+8,654
| New | +$308K |
|
2960
Center Bancorp
CNOB
$1.62B
| $321K | ﹤0.01% |
19,642
-4,576
| -19% | -$74.5K |
|
2961
Forrester Research
FORR
$232M
| $321K | ﹤0.01% |
9,561
-5,440
| -36% | -$168K |
|
2962
Immunic
IMUX
$228M
| $321K | ﹤0.01% |
88
+41
| +87% | +$142K |
|
2963
CALL
Capital One
COF
$132B
| $319K | ﹤0.01% |
4,600
-35,400
| -89% | -$2.34M |
|
2964
Jones Lang LaSalle
JLL
$17.7B
| $318K | ﹤0.01% |
+2,712
| New | +$329K |
|
2965
UBS Group
UBS
$164B
| $318K | ﹤0.01% |
19,845
+1,300
| +7% | +$21.1K |
|
2966
Chegg
CHGG
$87.7M
| $317K | ﹤0.01% |
71,168
+47,093
| +196% | +$239K |
|
|
EPAY
2967
DELISTED
Bottomline Technologies Inc
EPAY
| $317K | ﹤0.01% |
10,399
-7,901
| -43% | -$226K |
|
|
ELGX
2968
DELISTED
Endologix Inc
ELGX
| $317K | ﹤0.01% |
3,790
-5,165
| -58% | -$426K |
|
|
SBNY
2969
DELISTED
Signature Bank
SBNY
| $317K | ﹤0.01% |
2,326
-76,043
| -97% | -$10.4M |
|
2970
Cavco Industries
CVCO
$4.53B
| $316K | ﹤0.01% |
3,386
-10,185
| -75% | -$839K |
|
2971
Omnicom Group
OMC
$24.1B
| $316K | ﹤0.01% |
3,793
-65,986
| -95% | -$4.97M |
|
|
VASC
2972
DELISTED
Vascular Solutions Inc
VASC
| $315K | ﹤0.01% |
+9,680
| New | +$279K |
|
|
QIWI
2973
DELISTED
QIWI PLC
QIWI
| $315K | ﹤0.01% |
+21,772
| New | +$291K |
|
2974
Kadant
KAI
$3.67B
| $313K | ﹤0.01% |
6,933
-2,591
| -27% | -$103K |
|
2975
Tonix Pharmaceuticals
TNXP
$219M
| – | – |
0
| – | – |
|
Similar funds
David Shaw's Q1 2016 Portfolio in Review
As of Q1 2016, David Shaw held 4,137 positions worth $55.7B, down 17% from $67.2B the previous quarter. Its ten largest holdings account for 9.5% of the portfolio.
David Shaw withdrew a net $9.72B in Q1 2016, closing 773 positions and reducing 1,495 holdings. Its most notable exit was PRECISION CASTPARTS CORP, an estimated $637M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 14% of assets, up from 13% a quarter earlier, followed by Technology and Financials.
Against the trend, David Shaw opened a new position in EQT Corp worth $47.6M.
- David Shaw's largest Q1 2016 buy was EQT Corp: 1,300,361 shares worth $47.6M.
- David Shaw added most to Allergan plc in Q1 2016, an estimated $397M increase.
- David Shaw's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $358M.
- David Shaw fully exited PRECISION CASTPARTS CORP in Q1 2016, selling an estimated $637M.
- David Shaw's ten largest holdings make up 9.5% of its $55.7B portfolio in Q1 2016.
- David Shaw opened 382 new positions and closed 773 in Q1 2016.
- David Shaw's portfolio value fell 17% quarter-over-quarter to $55.7B.
Based on D.E. Shaw & Co's 13F filing for Q1 2016, filed 16 May 2016.